70 likes | 253 Views
www.italiansarcomagroup.org. I. I. talian. talian. Started June 1997. S. S. arcoma. arcoma. G. G. roup. roup. Formalized October 2002. 6. 8. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1. 2. 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 5. 3. 3. 2. 1.
E N D
www.italiansarcomagroup.org I I talian talian Started June 1997 S S arcoma arcoma G G roup roup Formalized October 2002
6 8 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 5 3 3 2 1 Italian Sarcoma Group 1 BELGIUM 68 Centers • 14 National Institutes • 14 Universities • 34 Pubblic Hospitals • 6 Private Hospitals 1 1 10 210 members at november 2005
Italian Sarcoma Group Osteosarcoma Protocols •ISG/SSG I (localized disease): 3/1997 - 3/2001, 182 pts ClosedJCO 2005 • ISG/SSG II (metastatic disease): 3/1998 - 12/2002, 57 ptsClosedASCO 2005 • ISG/OS I (localized disease) activated 4/2001, 237 pts • EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 120 pts • High risk (relapsed patients) activated 12/2002, 36 pts •H.D. Samarium + PBSCR in multiple bone lesions activated 11/2005, 6 pts
Italian Sarcoma Group Ewing’s Sarcoma Protocols • ISG/SSG III (standard risk) activated 6/99, 264 pts ASCO 2007 • ISG/SSG IV (high risk) activated 6/99, 82 pts ASCO 2005 • ISG/AIEOP (very high risk) activated 12/2002, 25 pts Closed In press EJC 2006 • Relapsed Patients activated 12/2002, 32 pts ASCO 2007 ?
Italian Sarcoma Group Adult soft tissue sarcomas - Protocols • ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk localized disease) with Spanish Group (282 pts) • ISG/STS 03/02 (neodjuvant IFO+RT in retroper. (30 pts) • HD-IFX in continuous infusion (2nd-4th line) (32 pts) • Gemcytabine in leiomyosarcomas (2nd-3rd line) (20 pts) • MiniallogenicTransplant(advanced disease, responsive patients) (6 pts) •Phase 2 Trabectedin in myxoid liposarcoma Other • Imatinib in advanced chordoma (50 pts) (ASCO 2007)
GIST Protocols • • GIOTTO (observational, 2004-2005, in collaboration with Novartis) (790 pts) Closed • • REGISTER (retrospective, histhological) (470 pts) • • 62024 (adjuvant Imatinib), intergroup with EORTC (49/418 pts) • • Institutions from the ISG are participating in the following studies on new agents in GIST: • Sunitinib (international) • •PTK787 (international) • • Nilotinib (international)
In preparation • Osteosarcoma: localized disease • Ewing’s sarcoma: localized disease • Soft tissue sarcomas: high risk, localized • Surgery in GIST after Imatinib (intergroup) • Imatinib in localized chordoma • Imatinib in Chs and fibromatosis